// App-Quantinova.ai

BSH19‐OR‐026 : Diffuse large B‐cell lymphoma remodels the fibroblastic reticular network that acquires aberrant immunosuppressive capabilities; implications for the regulation of anti‐tumor immunity in the immuno‐oncology era.

Researchers

Presenter

  • B. Apollonio

Principal Investigators

  • P. Jarvis

  • E. Phillips

  • A. Kuhnl

  • J. Salisbury

  • G. Zacharioudakis

  • L.-A. Sutton

  • R. Rosenquist

  • R. Jarrett

  • R.-M. Amini

  • A. Vardi

  • A. Ramsay

Medical Centers

  • Faculty of Life Sciences and Medicine, Kings College London, London

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • 1st Propedeutic Surgical Department, Aristotle University of Thessaloniki, Greece

  • Karolinska Institutet, Stockholm, Sweden

  • University of Glasgow, Glasgow, United Kingdom

  • Uppsala University Hospital, Uppsala, Sweden

  • Institute of Applied Biosciences, CERTH

  • Hematology Department/ BMT unit, G.Papanicolaou General Hospital, Thessaloniki, Greece

Locations

  • United Kingdom

  • Greece

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Solid malignancies

Biomarkers

  • B-cell activating factor

  • C-C Motif Chemokine Ligand 21

  • Cluster of differentiation 8A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved